Feedback
Settings

Settings

Goto Application

1. WO2022117448 - CRYSTALLINE FORMS OF PRALSETINIB

Submit observation
PermaLink
Publication Number WO/2022/117448
Publication Date 09.06.2022
International Application No. PCT/EP2021/083135
International Filing Date 26.11.2021
IPC
C07D 401/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61K 31/506 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
Applicants
  • SANDOZ AG [CH]/[CH]
Inventors
  • LENGAUER, Hannes
  • PICHLER, Arthur
  • MARGREITER, Renate
Agents
  • KLUSCHANZOFF, Harald
  • HOTTER, Andreas
Priority Data
20211574.703.12.2020EP
21155000.903.02.2021EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) CRYSTALLINE FORMS OF PRALSETINIB
(FR) FORMES CRISTALLINES DE PRALSETINIB
front page image
Abstract
(EN) The present invention relates to crystalline forms of pralsetinib and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of the crystalline forms of pralsetinib of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of RET-associated cancers, such as non-small cell lunc cancer and thyroid cancer.
(FR) La présente invention concerne des formes cristallines de pralsetinib ainsi que leurs procédés de préparation. En outre, l'invention concerne une composition pharmaceutique comprenant une des formes cristallines du pralsetinib de la présente invention et au moins un excipient pharmaceutiquement acceptable. La composition pharmaceutique de la présente invention peut être utilisée en tant que médicament, en particulier pour le traitement de cancers associés à RET, tels que le cancer du poumon à cellules non petites et le cancer de la thyroïde.
Latest bibliographic data on file with the International Bureau
# -